Read Time:7 Second
The deal is bid to strengthen Amgen’s drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
